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Non-small cell lung cancer (NSCLC) is the leading cause of cancer-
related death in the United States. Angiogenesis, primarily mediated
through vascular endothelial growth factor (VEGF), is one of the
key steps in tumor growth and metastasis. VEGF is now a validated
target for NSCLC based on the results of the Eastern Cooperative
Oncology Group trial E4599 which showed that the addition of
bevacizumab, a VEGF monoclonal antibody, to cytotoxic chemo-
therapy improves survival compared with chemotherapy alone in
patients with metastatic NSCLC. As NSCLC has complex and
integrated signaling pathways, a rational approach is to target more
than one of these pathways concurrently. Sorafenib, which is ap-
proved for the treatment of renal cell carcinoma, is a multitargeted
signal transduction inhibitor that inhibits raf-kinases, VEGF recep-
tor-2, platelet derived growth factor receptor-B, and c-kit. In a phase
II monotherapy trial in patients with previously treated NSCLC,
sorafenib demonstrated activity with a disease control rate and
survival rate comparable to other small molecules. Additionally,
sorafenib has shown preliminary activity in combination with che-
motherapy and with epidermal growth factor receptor inhibitors.
Future directions will include the development of rational combina-
tions either with cytotoxic compounds or biologically targeted
compounds and the identification of subsets of patients that might
benefit from the other targets of sorafenib.
Key Words: NSCLC, TKI, Proangiogenic, VEGFR, Raf kinase.
(J Thorac Oncol. 2008;3: Suppl 2, S124–S127)
Cytotoxic chemotherapy remains the standard therapeuticapproach for the majority of patients with metastatic
non-small cell lung cancer (NSCLC). Chemotherapy regi-
mens, either as a platinum-based doublet or as a single agent
serve as the mainstay for the treatment of patients with
metastatic NSCLC.
Four standard platinum-based regimens were compared
in a randomized trial of 1155 patients with untreated ad-
vanced inoperable NSCLC. There was no statistically signif-
icant difference between the different regimens in regards to
response rate, 1 year, 2 year, or overall survival (OS).1 Similarly,
no significant difference in response rate, median survival, or
1-year survival was seen in a large randomized trial comparing
docetaxel and pemetrexed in patients with previously treated
NSCLC.2 Cytotoxic chemotherapy has plateaued in terms of
efficacy and new approaches are warranted.
As we have improved our understanding of cancer biol-
ogy, we have seen the development of new classes of thera-
peutic agents that are capable of specifically targeting the
tumor cell or its supporting milieu. A treatment strategy that
has shown promise is inhibition of angiogenesis, the devel-
opment of new blood vessels. To grow beyond a few milli-
meters in diameter, solid tumors must develop a vascular
supply.3 Chief among the mediators of angiogenesis is vas-
cular endothelial growth factor (VEGF).
VEGF is a proangiogenic molecule and is a key con-
tributor to the angiogenesis pathway. As its receptors are ex-
pressed primarily on endothelial cells and its protein expression
levels are increased on tumor endothelium, the VEGF axis is an
ideal target for therapeutic intervention. VEGF regulates several
different functions including maintenance of established vessels
and promotion of tumor angiogenesis.4 Therefore, inhibition of
neovascularization through blockade of the VEGF axis can
result in growth arrest and decrease the potential for the forma-
tion of metastatic deposits.
There are a number of strategies through which the
effects of VEGF can be inhibited. Targeting the ligand with
monoclonal antibodies such as bevacizumab has proven
highly successful in a broad range of tumors.5,6 Bevacizumab
is a recombinant humanized monoclonal antibody to VEGF.7
In Phase I clinical trials, bevacizumab was well tolerated both
as a monotherapy and when given in combination with
cytotoxic chemotherapy.8 Bevacizumab is the first antiangio-
genic agent to be approved for use based on a pivotal study
demonstrating improved OS for patients with colorectal can-
cer who received combination of bevacizumab with irinote-
can, 5-fluorouracil, and leucovorin.5 Sandler and colleagues
reported the results of a randomized phase III trial of exam-
ining the addition of bevacizumab (B) to a standard chemo-
therapy doublet, paclitaxel/carboplatin in patients with che-
monaive metastatic NSCLC. This study demonstrated the
superiority of PCB to paclitaxel/carboplatin with statistically
significant improvements in median survival (12.5 months
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versus 10.2 months), response rate (27% versus 10%), and
progression-free survival (PFS) (6.4 months versus 4.5
months).6
Though not as well studied in NSCLC, the approach of
blocking VEGF and other receptor tyrosine kinase pathways via
multitargeted signal transduction inhibitors has also demon-
strated proof of principle in several different solid tumors.9–11
SORAFENIB IN NSCLC
BAYER 43-9006 (Sorafenib) is a potent oral multitar-
geted signal transduction inhibitor. Specifically, sorafenib
inhibits VEGFR-2, raf-Kinases, platelet derived growth fac-
tor beta (PDGFR-B), and c-kit.12 Sorafenib has been evalu-
ated as a single agent at a dose of 400 mg orally twice daily
in multiple tumor types and has been approved in renal cell
cancer and more recently hepatocellular carcinoma based on
the results of randomized phase III trials.
Escudier reported the results of a large randomized trial
of 884 patients with advanced renal cell cancer who were
randomized to either 400 mg twice daily of sorafenib or
placebo. The pts treated on the sorafenib arm achieved a PFS
of 24 weeks versus12 weeks for those randomized to place-
bo.9 Principle toxicities included skin rash (34%), diarrhea
(33%), fatigue (26%), and hypertension (11%). Hand-foot
syndrome (HFS) was seen in 27% of patients treated with
sorafenib. In 2007, Llovet presented the results of a phase III
randomized placebo controlled trial in hepatocellular carci-
noma.10 In this trial, 602 patients were randomized in a one to
one fashion to either placebo or the standard dose of sorafenib
of 400 mg twice daily. This study met early stopping criteria
with an improvement in OS of 44% (10.7 months versus 7.9
months) favoring the sorafenib arm with a hazard ratio of
0.69.10 Toxicities associated with sorafenib were similar to
those reported in other single agent trials with the most
frequently reported adverse events including diarrhea (11%),
fatigue (10%), and HFS (8%). Sorafenib is now being studied
in different settings in NSCLC.
SINGLE AGENT ACTIVITY
Results of a phase II trial in patients with untreated
advanced or metastatic NSCLC were reported this past
year.13 In this phase II trial, patients with chemo-naive IIIB
(with malignant pleural effusion) or stage IV disease received
single agent sorafenib. This study used a Flemming two-stage
design and did not meet its prespecified efficacy endpoints.
Twenty-five patients were enrolled and evaluable for re-
sponse and toxicity. The most common grade 3 adverse
events were fatigue (20%), diarrhea (8%), and dyspnea (8%)
with one patient having a grade 4 pulmonary hemorrhage.
Three patients had a PR and 7 patients had SD. PFS and MS
were 2.9 months and 8.8 months respectively.13
Sorafenib has also demonstrated activity in patients
with previously treated NSCLC. A Phase II single arm study
of sorafenib in patients with refractory or recurrent NSCLC
was recently completed. Eligible patients had metastatic
NSCLC including squamous cell carcinoma, ECOG PSO-2,
and were allowed one to two prior therapies for their disease.
Fifty-two patients were enrolled at two participating centers
with 48 patients evaluable for the primary end point, response
rate. Although there were no partial responses (PRs), 30
patients had stable disease (SD) with 23 of those patients
demonstrating some degree of tumor shrinkage. The time to
tumor pogression reported was 103 days. Adverse events
(grade 3 or 4) included HFS and fatigue. There were two
patients with grade 3 hemoptysis, one of whom subsequently
developed grade 5 hemoptysis 30 days after discontinuation
of drug.14
IN COMBINATION WITH CHEMOTHERAPY
Aside from the inherent antitumor activity of com-
pounds such as sorafenib, another possible mechanism of
action supporting the use of angiogenesis inhibitors in com-
bination with cytotoxic chemotherapy is the potential to
improve delivery of chemotherapy. Tumors have increased
interstitial pressure secondary to the development of tortuous
and leaky blood vessels. The utilization of agents that inhibit
angiogenesis leads to normalization of tumor interstitial pres-
sure through pruning of these new, abnormal blood vessels,
allowing improved blood flow, increased delivery of chemo-
therapy to the tumor, and thus improved efficacy.15
Sorafenib at 400 mg twice daily has been combined
successfully with chemotherapy without evidence of pharma-
cokinetic interaction when given on days 2 to 19 of a 21 day
chemotherapy cycle.16 The combination of paclitaxel and
carboplatin with sorafenib resulted in PRs in 11 of 35 patients
with melanoma,. In a subset of 14 patients with metastatic
NSCLC, four achieved a PR, and seven SD, with a median
PFS of 34 weeks.16,17 The regimen was well tolerated and the
common treatment related events included rash (60%), HFS
(20%), and diarrhea (20%).
Based on the preliminary activity and acceptable safety
profile of this combination, several randomized phase III
studies in NSCLC have been undertaken. One of these trials,
ESCAPE, which compares the doublet of paclitaxel (200
mg/m2) and carboplatin (AUC 6) versus the same regimen
with the addition of sorafenib at 400 mg twice daily (days
2–19) in chemo-naive patients with advanced NSCLC com-
pleted accrual of 900 patients this past year (Figure 1). A
second phase III trial, combining sorafenib with gemcitabine
and cisplatin is currently open and accruing patients. Addi-
tional phase I and II studies are ongoing to further character-
ize the safety and efficacy of combinations of sorafenib with
various cytotoxic regimens in multiple settings in patients
with metastatic NSCLC.18
IN COMBINATION WITH BIOLOGIC THERAPIES
The rationale for the addition of sorafenib to agents that
target the epidermal growth factor is predicated on several
hypotheses. One assumption is that resistance to epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKI) may be in part mediated by the presence of K-ras
mutations. The addition of sorafenib to EGFR TKIs such as
gefitinib or erlotinib may overcome resistance to EGFR TKIs
in patients whose tumors express K-ras mutations. A second
hypothesis involves the shared downstream pathways of
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VEGF and EGFR signaling and that simultaneous inhibition
of both pathways may prove to be additive or syngeristic.19,20
In 2007, Adjei et al.21 reported the results of a phase I
trial evaluating the combination of sorafenib with the EGFR
TKI gefitinib in patients with metastatic or recurrent NSCLC.
This uniquely designed study consisted of 2 parts. Part A was
a standard dose escalation with sorafenib being dose esca-
lated from 200 mg twice daily to 400 mg twice daily while
being given in combination with the standard dose of gefitinib
at 250 mg once daily. Once the phase II dose was established
in part A, part B began accrual and patients were randomized
to either single agent gefitinib or sorafenib for 21 days
followed by a 7 day washout period and cross over to receive
the other drug as a single agent for 21 days. After completing
this run-in portion patients then received both drugs concur-
rently on a 28 day cycle until disease progression or unac-
ceptable toxicity. Thirty-two patients were enrolled in this
single center trial with 31 evaluable for both safety and
efficacy. Twelve patients were enrolled in part A (six in each
cohort) and 20 were enrolled in part B. One dose limiting
toxicity, elevated alanine aminotransferase, was seen at full
dose of both drugs. One PR was observed (in a patient
receiving 4th line therapy in part A) and 20 patients achieved
SD (eight patients from part A and 12 from part B). Median
PFS was 19 weeks. On the basis of this trial, the recom-
mended phase II dose of this combination is sorafenib 400 mg
twice daily with gefitinib 250 mg daily. The authors charac-
terized the drug-related toxicities as mild to moderate with
activity similar to that seen with other biologics compounds
in NSCLC.21
Duran reported the results of a phase I trial evaluating
the combination of erlotinib and sorafenib.22 Eligible patient
had a diagnosis of a metastatic solid tumor, ECOG PS 0-2,
treatment naive regards EGFR or VEGF targeting agents, and
unlimited prior therapies. Seventeen patients with 14 differ-
ent tumor types were enrolled on study in 3 cohorts with the
recommended phase II dose of this combination being sor-
afenib 400 mg twice daily and erlotinib 150 mg daily.
Erlotinib did not impact the pharmacokinetic profile of sor-
afenib. The most frequently reported grade 3 or 4 adverse
events included hypophosphatemia, fatigue, rash, vomiting,
and diarrhea. Of the 15 evaluable patients for response, three
had a PR and nine SD.22 Of note, none of the enrolled patients
had a diagnosis of NSCLC.
The concept of dual inhibition of the VEGF signaling
pathway is another logical therapeutic approach and the
combination of sorafenib with bevacizumab is being explored
in several phase I trials. Azad et al.23,24 reported the results of
a phase I combination study of sorafenib and bevacizumab in
patients with previously treated solid tumors. The maximum
tolerated dose was sorafenib 200 mg twice daily (days 1–5
each week) and bevacizumab 5 mg/kg once every 2 weeks
FIGURE 1. Schema depicting design of a com-
pleted randomized phase III trial comparing pacli-
taxel/carboplatin with or without sorafenib.
FIGURE 2. Schema depicting design of ongoing
phase I trial evaluating paclitaxel/carboplatin/bev-
acizumab with sorafenib.
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administered on a 2 week cycle. The regimen proved effica-
cious with PRs in 7 of 34 patients. Hypertension, proteinuria,
and thrombocytopenia were the most common grade 3 to 4
toxicities. Despite a maximum tolerated dose at lower doses
than recommended for either drug, efficacy and toxicity were
increased. Additional studies are ongoing and include a phase
I dose escalation study combining sorafenib with the PCB
combination in patients with untreated advanced or metastatic
NSCLC (Figure 2).
CONCLUSIONS
NSCLC is a heterogeneous tumor whose growth, with
rare exception, is dependent on the dysregulation of multiple
signaling pathways. This simultaneous activation of a multi-
tude of oncogenic pathways supports the utilization of com-
pounds that either have multiple targets and/or toxicity profiles
that allow for combinations with other therapeutic compounds.
The rational combination of drugs with different mechanisms of
actions could lead to improved efficacy over single agent ther-
apy through inhibition of potential mechanisms of resistance.
This is supported by the phase I and II results of the combination
of erlotinib and bevacizumab in NSCLC.19,25
Sorafenib, an oral mutitargeted TKI, is well tolerated as a
single agent with efficacy similar to that seen with other multi-
targeted TKIs in an unselected NSCLC patient population. The
next generation of clinical trials should focus on both patient
selection and rational combinations of sorafenib with other
therapeutic agents. Given the unique targets of sorafenib, which
include the VEGF, PDGF, and Raf/MEK kinase pathways,
future trials should identify patients whose tumors have biologic
signatures that match these known targets. Sorafenib has dem-
onstrated a capacity to be safely combined with multiple cyto-
toxic and biologic therapies.18,21–23,26 This allows for potential
combinations with the possibility of blocking multiple signaling
pathways at multiple points. As has been reported in exploratory
trials, novel combinations with sorafenib have demonstrated
promising activity. Our ability to best use compounds like
sorafenib in selected populations or in combination with other
therapeutics will ultimately be linked to development of vali-
dated biomarkers and improved techniques to measure these
biomarkers in both tissue and blood.
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